ArticleCell death discovery2025
Chemically induced dimerization of GSDMD C-terminal domain blocks GSDMD N-terminal domain-mediated pyroptosis.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The dual role of pyroptosis in prostate cancer: new perspectives from molecular mechanisms to clinical translation.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GSDMD is a pyroptosis executioner in which the C-terminal domain completely inhibits the pore-forming ability of the N-terminal domain. Caspase cleavage separates GSDMD into the free C-terminal fragment (GD-CT) and the free N-terminal fragment (GD-NT). Although GD-CT retains the ability to bind with GD-NT, it can no longer completely disable GD-NT, allowing the latter to oligomerize and form nano-sized pyroptotic pores in the plasma membrane. In this study, we report that GD-CT is strictly confined to the cytoplasm, whereas GD-NT is transported to the plasma membrane. Additionally, GD-CT undergoes rapid degradation via the 26S proteasome pathway. Therefore, we propose that the spatial separation and rapid turnover of GD-CT limit its efficacy in blocking GD-NT-mediated pyroptosis. Given these properties of GD-CT, we engineered an efficient pyroptosis blocker "FKBP-GD-CT". This chimera protein incorporates a myristoylation motif, which confers plasma membrane translocation capability, and an FKBP12F36V domain, which enables dimerization in response to the chemical inducer AP20187. This is the first report utilizing chemical-induced dimerization technology to modulate pyroptosis levels.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.